Dynavax completes Symphony Dynamo acquisition
This article was originally published in Scrip
Executive Summary
Dynavax Technologies has completed its acquisition of Symphony Dynamo, boosting its cash reserves and reacquiring the rights to its hepatitis C and cancer programmes.